WO2008057208A2 - Hcv ns3 protease inhibitors - Google Patents
Hcv ns3 protease inhibitors Download PDFInfo
- Publication number
- WO2008057208A2 WO2008057208A2 PCT/US2007/022452 US2007022452W WO2008057208A2 WO 2008057208 A2 WO2008057208 A2 WO 2008057208A2 US 2007022452 W US2007022452 W US 2007022452W WO 2008057208 A2 WO2008057208 A2 WO 2008057208A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- ring
- heterocyclyl
- Prior art date
Links
- 0 C(CC1)CCC1*(C1CCCCC1)C1CCCCC1 Chemical compound C(CC1)CCC1*(C1CCCCC1)C1CCCCC1 0.000 description 4
- SFWFXUUDMPAFIT-LGTAJCCKSA-N CCOC([C@@](C1)(C1C=C)NC([C@H](C/C(/C1)=[O]/c2c(cc(C=C)c(OC)c3)c3nc(-c3ccccc3)c2)N1C([C@H](CCCCCC=C)NC(OCC(C)(C)CC=C)=O)=O)=O)=O Chemical compound CCOC([C@@](C1)(C1C=C)NC([C@H](C/C(/C1)=[O]/c2c(cc(C=C)c(OC)c3)c3nc(-c3ccccc3)c2)N1C([C@H](CCCCCC=C)NC(OCC(C)(C)CC=C)=O)=O)=O)=O SFWFXUUDMPAFIT-LGTAJCCKSA-N 0.000 description 1
- FAIISMHJUHDVPR-RISCZKNCSA-N CCOC([C@H](C1)NC[C@@H]1Oc1c(cc(c(OC)c2)Br)c2ccn1)=O Chemical compound CCOC([C@H](C1)NC[C@@H]1Oc1c(cc(c(OC)c2)Br)c2ccn1)=O FAIISMHJUHDVPR-RISCZKNCSA-N 0.000 description 1
- RFHZYGOURTUGBW-MHKYCTGGSA-N CCOC([C@H](CC(C1)Oc2nccc(cc3OC)c2cc3Br)N1C([C@H](CCCCCC=C)NC(OC(C)(C)C)=O)=O)=O Chemical compound CCOC([C@H](CC(C1)Oc2nccc(cc3OC)c2cc3Br)N1C([C@H](CCCCCC=C)NC(OC(C)(C)C)=O)=O)=O RFHZYGOURTUGBW-MHKYCTGGSA-N 0.000 description 1
- SWZSRHQXMVTYAK-HIFRSBDPSA-N COC([C@H](C1)NC[C@@H]1OC(N1Cc2c(C=C)cccc2C1)=O)=O Chemical compound COC([C@H](C1)NC[C@@H]1OC(N1Cc2c(C=C)cccc2C1)=O)=O SWZSRHQXMVTYAK-HIFRSBDPSA-N 0.000 description 1
- VJWLXXSILUTTTR-RISCZKNCSA-N COC([C@H](C1)NC[C@@H]1OC(c(c(N1)c2)cc(C=C)c2OC)=CC1=O)=O Chemical compound COC([C@H](C1)NC[C@@H]1OC(c(c(N1)c2)cc(C=C)c2OC)=CC1=O)=O VJWLXXSILUTTTR-RISCZKNCSA-N 0.000 description 1
- OCCVDBRQKIOJDC-CRNUAONWSA-N COc1cc2nc(-c3ccccc3)cc(/[O]=C\C(C[C@H]3C(NC(CC=C)C(NS(C4CC4)(=O)=O)=O)=O)CN3C([C@H](CCCCCC=C)NC(OCCCC=C)=O)=O)c2cc1C=C Chemical compound COc1cc2nc(-c3ccccc3)cc(/[O]=C\C(C[C@H]3C(NC(CC=C)C(NS(C4CC4)(=O)=O)=O)=O)CN3C([C@H](CCCCCC=C)NC(OCCCC=C)=O)=O)c2cc1C=C OCCVDBRQKIOJDC-CRNUAONWSA-N 0.000 description 1
- JAMYWQAHTSZTLQ-UKTPDREPSA-N O=C([C@@](C1)(C1/C=C\CCCCC[C@@H](C(N(C1)[C@H]2C[C@H]1Oc1cc(cccc3)c3nc1CCCCC[C@H](CCC1)[C@@H]1O1)=O)NC1=O)NC2=O)NS(C1CC1)(=O)=O Chemical compound O=C([C@@](C1)(C1/C=C\CCCCC[C@@H](C(N(C1)[C@H]2C[C@H]1Oc1cc(cccc3)c3nc1CCCCC[C@H](CCC1)[C@@H]1O1)=O)NC1=O)NC2=O)NS(C1CC1)(=O)=O JAMYWQAHTSZTLQ-UKTPDREPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to macrocyclic compounds that are useful as inhibitors of the hepatitis C virus (HCV) NS 3 protease, their synthesis, and their use for treating or preventing HCV infection.
- HCV hepatitis C virus
- HCV infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population.
- HCV human immunodeficiency virus
- WHO World Health Organization
- NS3 protease is located in the N-terminal domain of the NS3 protein, and is considered a prime drug target since it is responsible for an intramolecular cleavage at the NS3/4A site and for downstream intermolecular processing at the NS4A/4B, NS4B/5A and NS5 A/5B junctions.
- NS4A is a cofactor for NS3 protease activity.
- the present invention relates to novel macrocyclic compounds of formula (I) and/or pharmaceutically acceptable salts or hydrates thereof. These compounds are useful in the inhibition of HCV (hepatitis C virus) NS3 (non-structural 3) protease, the prevention or treatment of one or more of the symptoms of HCV infection, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HCV antivirals, anti- infectives, imrnunomodulators, antibiotics or vaccines. More particularly, the present invention relates to a compound of formula (I) and/or a pharmaceutically acceptable salt, hydrate or prodrug thereof:
- a heterocyclic ring system wherein the points of attachment to variables Y and X are independently selected from a first pair of atoms comprising a first carbon ring atom and second carbon ring atom, and a second pair of atoms comprising a carbon ring atom and a nitrogen ring atom, and the heterocyclic ring system is selected from the group consisting of: a) a 5- or 6- membered saturated or unsaturated monocyclic ring with 1, 2, or 3 heteroatom ring atoms selected from the group consisting of N, O or S, b) an 8-, 9- or 10-membered saturated or unsaturated bicyclic ring with 1, 2, or 3 heteroatom ring atoms selected from the group consisting of N, O or S, and c) an 11 - to 15-membered saturated or unsaturated triicyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N,
- R 1 is CO 2 R 10 , CONR 10 SO 2 R 6 , CONR 10 SO 2 NR 8 R 9 , tetrazolyl, CONHP(O)R 11 R 12 , Or P(O)R 11 R 12 ;
- R 5 is H, halo, OR 10 , C 1 -C 6 alkyl, CN, CF 3 , SR 10 , SO 2 (Ci-C 6 alkyl), C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkoxy, CpC 6 haloalkyl, N(R 7 ) 2 , aryl, heteroaryl or heterocyclyl; wherein aryl is phenyl or naphthyl, heteroaryl is a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and heterocyclyl is a 5- to 7-membered saturated or unsaturated non- aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen; and wherein said aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkoxy, alkyl or alk
- R 6 is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl(C 1 -C 5 )alkyl, aryl, aryl(Ci- C 4 )alkyl, heteroaryl, heteroaryl(Ci-C 4 alkyl), heterocyclyl, or heterocyclyl(Ci-Cg alkyl), wherein said alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with 1 to 2 W substituents; and wherein each aryl is independently phenyl or naphthyl, each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S
- alkylene, alkenylene and alkynylene is unsubstiruted or substituted with Ci -6 alkyl;
- Y is selected from the group consisting of:
- each alkylene, alkenylene and alkynylene is unsubstituted or substituted with C 1-6 alkyl, any two adjacent carbon atoms in Y optionally form a C 3-6 membered ring containing O to 3 heteroatoms selected from the group consisting of N, O and S, and each alkylene, alkenylene and alkynylene chain optionally includes an oxygen atom in place of a methylene moiety;
- each R 7 is independently H, Cj-C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl(Ci-C 5 )alkyl, aryl, aryl(C !
- each aryl is independently phenyl or naphthyl
- each heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen
- each heterocyclyl is independently a 5- to 7-membered saturated or unsaturated non-aromatic ring having 1, 2, 3 or 4 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen
- each W is independently halo, OR 10 , C 1 -C 6 alkyl, CN, CF 3 , NO 2 , SR 10 , CO 2 R 10 ,
- R 8 is Ci-C 8 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl(C r C 8 alkyl), aryl, aryl(Ci-C 4 alkyl), heteroaryl, heterocyclyl, heteroaryl(Ci-C 4 alkyl), or heterocyclyl(d-C 8 alkyl), wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with 1 to 4 substituents selected from the group consisting of aryl, C 3 -C 8 cycloalkyl, heteroaryl, heterocyclyl, C-C 6 alkyl, ImIo(C 1 -C 6 alkoxy), halo, OR 10 , SR 10 , N(R 10 ) 2 , N(C 1 -C 6 alkyl)O(Ci-C 6 alkyl), C 1 -C 6 alkyl, C(O)R 10
- R 14 is Cj-C 6 alkyl, C 2 -C 6 alkenyl, aryl or heteroaryl, wherein aryl is phenyl or naphthyl, and heteroaryl is independently a 5- or 6-membered aromatic ring having 1, 2 or 3 heteroatoms selected from N, O and S, attached through a ring carbon or nitrogen, and wherein said aryl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of C r C 6 alkyl, halo, OC(O)OR 6 , OC(O)R 6 , OR 10 , SR 10 , N(R 10 ) 2 , C(O)R 10 , NO 2 , CN, CF 3 , SO 2 (Ci-C 6 alkyl), S(O)(Cj-C 6 alkyl), NR 10 SO 2 R 6 , SO 2 N(R 6 ) 2 , NHCOOR 6 , NHCOR 6 , NHCONHR 6
- R 17 is Ci -6 alkyl or a Ci -6 alkylene moiety that, together with another carbon atom in Y, forms a heterocyclic ring containing one nitrogen and 2-7 carbon atoms.
- X is -Co -5 alkylene-O- or -C 0-3 alkylene-C(0)O. In a preferred group of this embodiment, X is -O- or -C(O)O-.
- Y is -Ci -7 alkylene-Y 1 - or -C 2-7 alkenylene-Y 1 -, wherein Y 1 is -OC(O)- or-C(O)-, and each alkylene, alkenylene and alkynylene is unsubstituted or substituted with Cj -2 alkyl.
- Y is selected from the group consisting of:
- Z is -(CH 2 ) 3 -.
- A is selected from the group consisting of:
- R 5 is selected from the group consisting of H, -OCi -6 alkyl and phenyl, and p and q are 1.
- A is selected from the group consisting of:
- a fifth embodiment provides a combination of 2, 3 or 4 of the above-described first through fourth embodiments.
- the compound is selected from the group consisting of the compounds listed in Examples 1-6 and shown in Tables A, B, and C.
- the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
- the present invention further includes methods of treating or preventing one or more symptoms of HCV infection.
- the present invention includes compounds of formula I above, and pharmaceutically acceptable salts and/or hydrates thereof. These compounds and their pharmaceutically acceptable salts and/or hydrates are HCV protease inhibitors (e.g., HCV NS3 protease inhibitors).
- HCV protease inhibitors e.g., HCV NS3 protease inhibitors
- composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.
- composition of (b), wherein the HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
- a pharmaceutical combination which is (i) a compound of formula (I) and (ii) a second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent; wherein the compound of formula (I) and the second therapeutic agent are each employed in an amount that renders the combination effective for inhibiting HCV NS 3 protease, or for treating or preventing infection by HCV.
- HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
- HCV NS3 protease A method of inhibiting HCV NS3 protease in a subject in need thereof which comprises administering to the subject an effective amount of a compound of formula (I).
- HCV antiviral agent is an antiviral selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
- (j) A method of inhibiting HCV NS3 protease in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
- (k) A method of preventing or treating infection by HCV in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
- the present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) inhibiting HCV NS3 protease, or (b) preventing or treating infection by HCV.
- the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators .
- Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(k) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt or hydrate as appropriate.
- each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound and is consistent with the description of the embodiments.
- the embodiments of compositions and methods provided as (a) through (k) above are understood to include all embodiments of the compounds, including such embodiments as result from combinations of embodiments.
- alkyl refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range.
- Cj -6 alkyl (or “C 1 -C 6 alkyl”) refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
- C 1-4 alkyl refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
- haloalkyl refers to an alkyl group wherein a hydrogen has been replaced by a halogen.
- alkoxy refers to an "alkyl-O-" group.
- alkylene refers to any linear or branched chain alkylene group (or alternatively “alkanediyl”) having a number of carbon atoms in the specified range.
- -Ci -6 alkylene- refers to any of the Ci to C 6 linear or branched alkylenes.
- a class of alkyl enes of particular interest with respect to the invention is -(CH 2 )i -6 -, and sub-classes of particular interest include -(CH 2 ) I-4 -, -(CH 2 ) I-3 -, -(CH 2 )i -2 -, and -CH 2 -. Also of interest is the alkylene -CH(CH 3 )-.
- cycloalkyl refers to any cyclic ring of an alkane or alkene having a number of carbon atoms in the specified range.
- C 3-8 cycloalkyl (or “C 3 -C 8 cycloalkyl”) refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- cycloalkoxy refers to a "-O-cycloalkyl” group.
- halogen (or “halo" refers to fluorine, chlorine, bromine and iodine
- Het refers to a 5- to 6-membered saturated cyclic ring having 1 or 2 heteroatoms selected from N, O and S, wherein said ring is optionally substituted with 1 to 3 substituents selected from halo, OR 10 , SR 10 , N(R 10 ) 2 , N(Ci-C 6 alkyl)O(C r C 6 alkyl), Ci-C 6 alkyl, C 1 -C 6 haloalkyl, halo(C,-C 6 alkoxy), NO 2 , CN, CF 3 , SO 2 (C 1 -C 6 alkyl), S(O)(C-C 6 alkyl), NR 10 SO 2 R 6 , SO 2 N(R 6 ) 2 , NHCOOR 6 , NHCOR 6 , NHCONHR 6 , CO 2 R 10 , C(O)R 10 , and CON(R 10 ) 2 .
- carbocycle (and variations thereof such as “carbocyclic” or “carbocyclyl”) as used herein, unless otherwise indicated, refers to (i) a C 3 to C 8 monocyclic, saturated or unsaturated ring or (ii) a C 7 to Cj 2 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated.
- the carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
- fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term "fused bicyclic carbocycle” generally refers to a C 7 to Ci 0 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system.
- a fused bicyclic carbocycle in which one ring is saturated and the other is saturated is a saturated bicyclic ring system.
- a fused bicyclic carbocycle in which one ring is benzene and the other is saturated is an unsaturated bicyclic ring system.
- a fused bicyclic carbocycle in which one ring is benzene and the other is unsaturated is an unsaturated ring system.
- Saturated carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc.
- carbocycle is unsubstituted or substituted with C] -6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, halogen, NH 2 or OH.
- a subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include
- Depicted ring systems include, where appropriate, an indication of the variable to
- variable X ring atom 2
- ring atom 4 is directly attached to variable Z
- Variable R 5 is shown as a floating variable which can be attached to any ring atom, provided that such attachment results in formation of a stable ring.
- aryl refers to aromatic mono- and poly-carbocyclic ring systems, also referred to as “arenes”, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond.
- Suitable aryl groups include phenyl, naphthyl, and biphenylenyl.
- heterocycle broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, (ii) a stable 7- to 12-membered bicyclic ring system, or (iii) a stable 11- to 15-membered tricyclic ring stystem, wherein each ring in (ii) and (iii) is independent of, or fused to, the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring, bicyclic ring system or tricyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the bicyclic and tricyclic ring systems typically contain at least two
- the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
- the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
- saturated heterocyclics form a subset of the heterocycles.
- saturated heterocyclic generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated.
- saturated heterocyclic ring refers to a 4- to 8-membered saturated monocyclic ring, a stable 7- to 12-membered bicyclic ring system, or a stable 11- to 15-membered tricyclic ring system, which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
- Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl).
- unsaturated heterocyclics form another subset of the heterocycles.
- the term “unsaturated heterocyclic” generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is not saturated, i.e., such rings are either unsaturated or partially unsaturated.
- the term “heteroaromatic ring” refers a 5- or 6-membered monocyclic aromatic ring, a 7- to 12-membered bicyclic ring system, or an 11- to 15-membered tricyclic ring system, which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
- heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
- bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl,
- ⁇ O ⁇ $ alternatively referred to as phenyl having as a substituent methyl enedioxy attached to 2 adjacent carbon atoms.
- alkyl, cycloalkyl, aryl and heterocycle groups are unsubstituted or substituted.
- substituted alkyl “substituted C 3 -C 10 cycloalkyl”, “substituted aryl” and “substituted heterocycle” are intended to include the cyclic group containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound.
- the substituents are selected from the group which includes, but is not limited to, halo, Ci-C 20 alkyl, -CF 3 , -NH 2 , -N(Ci-C 6 alkyl) 2 , -NO 2 , oxo, -CN, -N 3 , -OH, -0(Ci-C 6 alkyl), C 3 -C 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 alkyl)-S(O) 0-2 -, aryl ⁇ S(O) 0-2 -, (C 0 -C 6 alkyl)S(O) 0-2 (C 0 -C 6 alkyl)-, (C 0 -C 6 alkyl)C(O)NH-, H 2 N-C(NH)-, -0(C 1 -C 6 alkyl)CF 3 , (
- heteroaryl ring described as containing from “1 to 3 heteroatoms” means the ring can contain 1, 2, or 3 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. The oxidized forms of the heteroatoms N and S are also included within the scope of the present invention.
- any variable e.g., R 7 and R 10
- its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- substitution by a named substituent is permitted on any atom in a ring (e.g., aryl, a heteroaromatic ring, or a saturated heterocyclic ring) provided such ring substitution is chemically allowed and results in a stable compound.
- a ring e.g., aryl, a heteroaromatic ring, or a saturated heterocyclic ring
- stable compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
- substituents and substituent patterns certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
- a reference to a compound of formula (I) is a reference to the compound per se, or to any one of its tautomers per se, or to mixtures of two or more tautomers.
- the compounds of the present inventions are useful in the inhibition of HCV protease (e.g., HCV NS3 protease) and the prevention or treatment of infection by HCV.
- HCV protease e.g., HCV NS3 protease
- the compounds of this invention are useful in treating infection by HCV after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
- the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
- the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
- the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HCV protease, e.g., by competitive inhibition.
- the compounds of this invention are commercial products to be sold for these purposes.
- the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
- pharmaceutically acceptable salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
- Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
- suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
- alkali metal salts e.g., sodium or potassium salts
- alkaline earth metal salts e.g., calcium or magnesium salts
- salts formed with suitable organic ligands such as quaternary ammonium salts.
- an acid addition salts which may,
- esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
- administration and variants thereof (e.g., “administering” a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment.
- administration and its variants are each understood to include concurrent and sequential provision of the compound or salt (or hydrate) and other agents.
- prodrug is intended to encompass an inactive drug form or compound that is converted into an active drug form or compound by the action of enzymes, chemicals or metabolic processes in the body of an individual to whom it is administered.
- composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
- pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
- subject (alternatively referred to herein as “patient”) as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
- the term "effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, hi one embodiment, the effective amount is a "therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated. In another embodiment, the effective amount is a "prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition whose likelihood of occurence or severity is being reduced. The term also includes herein the amount of active compound sufficient to inhibit HCV NS3 protease and thereby elicit the response being sought (i.e., an "inhibition effective amount").
- references to the amount of active ingredient are to the free acid or free base form of the compound.
- the compounds of the present invention can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
- the compounds of the invention can, for example, be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
- Liquid preparations suitable for oral administration e.g., suspensions, syrups, elixirs and the like
- Solid preparations suitable for oral administration can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like.
- Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as a solubility aid.
- injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 18 th edition, edited by A. R. Gennaro, Mack Publishing Co., 1990.
- the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
- mammal e.g., human
- One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
- Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
- the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- the present invention also relates to a method of inhibiting HCV NS3 protease, inhibiting HCV replication, or preventing or treating HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.
- Such therapeutic agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha- 1, R7025 (an enhanced interferon (Roche)), interferon-/?, interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
- Interferon- ⁇ includes, but is not limited to, recombinant interferon- ⁇ 2a (such as ROFERON interferon available from Hoffmann-LaRoche, Nutley, NJ), pegylated interferon- ⁇ 2a (PEGASYS), interferon- ⁇ 2b (such as Intron-A interferon available from Schering Co ⁇ ., Kenilworth, NJ), pegylated interferon-o2b (PEGINTRON), a recombinant consensus interferon (such as interferon alphacon-1), albuferon (interferon- ⁇ bound to human serum albumin (Human Genome Sciences)), and a purified interferon- ⁇ product.
- recombinant interferon- ⁇ 2a such as ROFERON interferon available from Hoffmann-LaRoche, Nutley, NJ
- PEGASYS pegylated interferon- ⁇ 2a
- interferon- ⁇ 2b such as Intron-A interferon available from Schering Co ⁇ ., Kenil
- Amgen's recombinant consensus interferon has the brand name FNFERGEN®.
- Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin.
- Viramidine represents an analog of ribavirin disclosed in WO 01/60379 (assigned to ICN Pharmaceuticals).
- the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease.
- HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication.
- Both substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, GB-2337262, WO 02/48116, WO 02/48172, and U.S. Patent No. 6,323,180.
- Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH).
- IMPDH is the rate-limiting enzyme on the biosynthetic route in de novo guanine nucleotide biosynthesis.
- Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH.
- inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication. Therefore, the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as VX-497, which is disclosed in
- WO 97/41211 and WO 01/00622 (assigned to Vertex); another IMPDH inhibitor, such as that disclosed in WO 00/25780 (assigned to Bristol-Myers Squibb); or mycophenolate mofetil [see A.C. Allison and E.M. Eugui, Agents Action. 44 (Suppl.): 165 (1993)].
- the compounds of the present invention may also be administered in combination with the antiviral agent amantadine (1-aminoadamantane) [for a comprehensive description of this agent, see J. Kirschbaum, Anal. Profiles Drug Subs. 12: 1-36 (1983)].
- the compounds of the present invention may also be administered in combination with the antiviral agent polymerase inhibitor R7128 (Roche).
- the compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 2'-C-branched ribonucleosides disclosed in R. E. Harry-O'Kuru, et al., J. Ore. Chem.. 62: 1754-1759 (1997); M. S. Wolfe, et al., Tetrahedron Lett.. 36: 7611- 7614 (1995); U.S. Patent No. 3,480,613 (25 November 1969); International Publication Number WO 01/90121 (29 November 2001); International Publication Number WO 01/92282 (6 December 2001); and International Publication Number WO 02/32920 (25 April 2002); and International Publication Number WO 04/002999 (8 January 2004); and International
- Such 2'-C-branched ribonucleosides include, but are not limited to, 2'-C-methyl- cytidine, 2'-C-methyl-uridine, 2'-C-methyl-adenosine, 2'-C-methyl-guanosine, and 9-(2-C- methyl-
- the compounds of the present invention may also be combined for the treatment of HCV infection with other nucleosides having anti-HCV properties, such as those disclosed in WO 02/51425 (4 July 2002), assigned to Mitsubishi Pharma Corp.; WO 01/79246,
- WO 02/32920, WO 02/48165 (20 June 2002), and WO2005003147 (13 January 2005)(including R1656, (2'i?)-2'-deoxy-2'-fluoro-2'-C-methylcytidine, shown as compounds 3 ⁇ 6 on page 77) assigned to Pharmasset, Ltd.; WO 01/68663 (20 September 2001), assigned to ICN Pharmaceuticals; WO 99/43691 (2 September 1999); WO 02/18404 (7 March 2002), US 2005/0038240 (17 February 2005) and WO2006021341 (2 March 2006), including 4'-azido nucleosides such as R1626, 4'-azidocytidine, assigned to Hoffmann-LaRoche; US 2002/0019363 (14 February 2002); WO 02/100415 (19 December 2002); WO 03/026589 (3 April 2003); WO 03/026675 (3 April 2003); WO 03/093290 (13 November 2003);: US 2003/0236216 (25 December 2003); US 2004/0006007 (8 January 2004); WO
- the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS5B polymerase.
- HCV NS5B polymerase inhibitors that may be used as combination therapy include, but are not limited to, those disclosed in WO 02/057287, US 6,777,395, WO 02/057425, US 2004/0067901, WO 03/068244, WO 2004/000858, WO 04/003138 and WO 2004/007512; the content of each is incorporated herein by reference in its entirety.
- HCV polymerase inhibitors include, but are not limited to, valopicitabine (NM-283; Idenix) and 2'-F- 2'-beta-methylcytidine (see also WO 2005/003147, assigned to Pharmasset, Ltd.).
- nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS3 protease inhibitors are selected from the following compounds:
- the compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in WO 01/77091 (18 October 2001), assigned to Tularik, Inc.; WO 01/47883 (5 July 2001), assigned to Japan Tobacco, Inc.; WO 02/04425 (17 January 2002), assigned to Boehringer Ingelheim; WO 02/06246 (24 January 2002), assigned to Istituto di Ricerche di Biologia
- non-nucleoside HCV NS5B polymerase inhibitors that are used in combination with the present HCV NS 3 protease inhibitors are selected from the following compounds:
- HCV NS3 protease inhibitory activity of the present compounds may be tested using assays known in the art.
- One such assay is HCV NS3 protease time-resolved fluorescence (TRF) assay as described below and in International Patent Application Publication WO2006/102087.
- TRF time-resolved fluorescence
- Other examples of such assays are described in e.g., International Patent Application Publication WO2005/046712.
- HCV NS3 protease inhibitors, such as those described herein have a Ki less than 50 ⁇ M, such as less than 10 ⁇ M, and less than 100 nM. Ki is determined by an NS3 protease assay.
- the assay is performed in a final volume of 100 ⁇ l in assay buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 15 % glycerol, 0.15 % Triton X- 100, 10 mM DTT, and 0.1 % PEG 8000.
- NS3 protease is pre-incubated with various concentrations of inhibitors in DMSO for 30 minutes. The reaction is initiated by adding the TRP peptide substrate (final concentration 100 nM).
- NS3 mediated hydrolysis of the substrate is quenched after 1 hour at room temperature with 100 ⁇ l of 500 mM MES, pH 5.5.
- Product fluorescence is detected using either a VICTOR V2 or FUSION fluorophotometer (Perkin Elmer Life and Analytical Sciences) with excitation at 340 nm and emission at 615 nm with a 400 ⁇ s delay. Testing concentrations of different enzyme forms are selected to result in a signal to background ratio (S/B) of 10-30.
- R is C 1-6 alkyl unless otherwise indicated.
- amine base such as triethylamine in ethanol or other suitable solvents
- the BOC group of 5 can be removed by treatment with acid, such as HCl in a suitable solvent e.g. dioxane or ethyl acetate, or trifluoroacetic acid either neat or diluted with a solvent such as dichloromethane to provide 6.
- acid such as HCl
- suitable solvent e.g. dioxane or ethyl acetate
- trifluoroacetic acid either neat or diluted with a solvent such as dichloromethane to provide 6.
- the appropriate haloisoindoline 13 may be formed either by reduction of an appropriate halo substituted phthalimide 12 with, for example, borane, or alternatively an appropriate halo-xylene (e.g. 3-bromo-oxylene) may be doubly brominated utilizing N-bromosuccinimide and then ring closed by treatment with an amine such as benzylamine in the presence of an organic or inorganic base (e.g. potassium bicarbonate) in a solvent (e.g. acetonitrile).
- an appropriate halo-xylene e.g. 3-bromo-oxylene
- an organic or inorganic base e.g. potassium bicarbonate
- a solvent e.g. acetonitrile
- the benzyl group of the resultant isoindoline 14 can then be removed, for example by treatment with ⁇ -chloroethylchloroformate (ACE-Cl), followed by treatment with an alcohol (e.g. methanol).
- ACE-Cl ⁇ -chloroethylchloroformate
- the haloisoindoline 13 can then be coupled with N-protected (e.g. BOC) trans-4-hydroxyproline methyl (or ethyl) ester (15), by treatment of the latter with carbonyldiimidazole, phosgene or triphosgene, followed by addition of the haloisoindoline, optionally in the presence of an amine base such as triethylamine.
- Vinylation of the resulting coupled product 16 to 17 and removal of the proline protecting group to afford 18, can then be carried out as described for the compounds in Scheme 1.
- Intermediates C can then be converted to compounds of the present invention by a number of alternative procedures.
- an intermediate C is coupled with an alkenyl carbamate derivative of 2(5)-t-butoxycarbonylamino-non-8-enoic acid (Acme Bioscience Inc.) is coupled with proline derivative 19, using a standard peptide coupling reagent such as EDC, HATU or BOP to give intermediate 20.
- a standard peptide coupling reagent such as EDC, HATU or BOP
- tetraolefin 21 which can be subjected to a double ring closing metathesis reaction to give 22.
- Bis macrocycle 22 can then be hydrolyzed to give carboxylic acid products 23, which via activation of the carboxylic acid, for example by N,N'- carbonyldiimidazole and reaction with cyclopropyanesulfonamide affords the corresponding acylsulfonamides 24.
- ester 20 can be hydrolyzed, coupled with (li?,25)-l-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide (X.A.Wang et al., WO 2003/099274) and macrocyclzed to give directly the acylsulfonamides 24.
- Scheme 4
- the macrocycles may be constructed in sequential fashion (Scheme 5).
- proline derivative 25 can be coupled with 2(5)-t-butoxycarbonylamino-non-8-enoic acid (Acme Bioscience Inc.) to afford 26, followed by hydrolysis of the proline ester and coupling with (li?,25)-l-amino-2- vinylcyclopropanecarboxylic acid (Beaulieu et al., 70 J. Org. Chem. 5869-5879 (2005)) to afford bis olefin 27.
- Macrocyclization by ring closing metathesis with an appropriate ruthenium or other metal catalyst affords macrocycle 28.
- a hydrogenation of the macrocyclic olefin may optionally be carried out.
- Cleavage of the BOC group with acid and formation of an unsaturated carbamate by reaction with an appropriate unsaturated alcohol, which has been activated with N,N'-carbonyldiimidazole, phosgene or triphosgene yields 29.
- Vinylation of 29 to give 30 can then be carried out in a number of different ways including: reaction with vinyltributyltin and an appropriate palladium catalyst e.g. Pd(PPh 3 ) 4 in a solvent such as toluene, DMF, DMSO, THF: reaction with potassium vinyltrifiuoroborate and an appropriate palladium catalyst (e.g.
- Olefin metathesis catalysts include the following Ruthenium based species: F. Miller et al., 118 J. AM. CHEM. SOC. 9606 (1996); G. Kingsbury et al., 121 J. Am. Chem. Soc. 791 (1999); H. Scholl et al., 1 ORG. LETT. 953 (1999); U.S. Patent Application Publication US2002/0107138; K. Furstner et al., 64 J. ORG. CHEM. 8275 (1999).
- the utility of these catalysts in ring closing metathesis is well known in the literature (e.g. Trnka and Grubbs, 34 Ace. CHEM. RES. 18 (2001).
- reaction mixture was stirred at RT for 1 hour, and ethyl (2S)-2-aminonon-8-enoate * HCl (0.85 g, 3.61 mmol) and 1 M aqueous NaOH (7.21 ml, 7.21 mmol) added, and the reaction mixture was heated to 5O 0 C for 15 hours. After cooling to RT, the reaction mixture was basified to pH 8 with IM aqueous NaOH and extracted with ether (3 x 200 ml). The combined organic phases were washed with water (100 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated.
- Step 7 r25 r )-2-((
- DOWTHERM A 450 mL was heated to reflux ( ⁇ 300 ° C).
- the mixture was cooled to RT; hexane (400 mL) was added; and the mixture was stirred for 30 minutes, filtered, and the solids washed with hexane to give the title compound (38 g).
- Step 4 1-t-Butyl 2-methyl (2£45y4- ⁇ rf4-bromophenyl)sulfonyl1oxylpyrrolidine-1.2- dicarboxylate
- Step 5 1-t-Butyl 2-methyl (25,4RV4-r(6-bromo-7-methoxy-2-phenylquinolin-4- vDox vipyrrolidine- 1 ,2-dicarboxvlate
- Step 6 1-f-Butyl 2-methyl ( " 25 l ,4/?V4-r( ' 7-niethoxy-2-phenyl-6-vinylquinolin-4- vPox yip yrrolidine- 1 ,2-dicarboxylate
- Step 2 1-t-Butyl 2-methyl (25 l ,4R)-4-r(6-bromo-7-methoxy-2-oxo-1.2-dihvdroquinolin-4- VDOXVIP yrrolidine- 1 ,2-dicarbox vlate
- Step 4 Methyl (4J?)-4-[(7-methoxy-2-oxo-6-vinyl-l,2-dihydroquinolin-4-yl)oxyl-L-prolinate hydrochloride
- Postassium bicarbonate (204 g, 2.04 mol) was suspended in CH 3 CN (12 L), and the mixture was heated to 80 0 C. Solutions of l-bromo-2,3-bis(bromomethyl)benzene (280 g, 0.82 mol in 500 mL CH 3 CN) and benzylamine (87.5 g, 0.82 mol in 500 mL CH 3 CN) were added concurrently via addition funnels over 1 hour. The reaction mixture was then stirred at 77°C for 16 hours. The contents of the reaction flask were cooled and filtered; the solvent was removed by evaporation; and the mixture was partitioned between IM K 2 CO 3 and EtOAc.
- Step 5 1-t-Butyl 2-methyl ( " 2S.4RV4- ⁇ r( " 4-vinyl-13-dihvdro-2H " -isoindol-2- yl)carbonylloxylpyrrolidine-L2-dicarboxylate
- Step 1 Ethyl 3 -ethoxy-3-iminopropanoate hydrochloride
- Step 3 6-Bromo-2-ethoxy-7-methoxyquinolin-4-ol
- DOWTHERM 300 mL
- DOWTHERM 30 mL
- the resulting solution was stirred at 250°C for 5 minutes, cooled to RT and filtered.
- the resulting cake was washed with hexane (3 x 50 mL), then dried to give the title product.
- Step 4 1-t-Butyl 2-methyl (2£4Ry4-r(6-bromo-2-ethoxy-7-methoxyquinolin-4- vOoxyipyrrolidine- 1 ,2-dicarboxylate
- Step 1 l-Bromo-4-iodo-2-methoxybenzene
- Step 3 ⁇ -Bromo-Q-methoxy- ⁇ -oxo-S ⁇ -dihvdrophenanthridine-S-carbonitrile
- Step 4 Methyl (4RV4-[(3-cvano-9-methoxy-8-vinyl-5,6-dihvdrophenanthridin-6-yl)oxy "
- Step 5 Methyl (4iO-4-f(7-methoxy-3-vinylquinolin-2-yl)oxy1-L-prorinate hydrochloride
- a solution of 1-t-butyl 2-methyl (25',4i?)-4-[(7-methoxy-3-vinylquinolin-2- yl)oxy]pyrrolidine-l,2-dicarboxylate (0.85 g, 1.98 mmol) in 4M HCl in dioxane (10 mL) was stirred at RT for two hours. The reaction mixture was concentrated, and the product was used with no further purification.
- LRMS (M+H-tBu) + 329.3.
- Step 1 Methyl (4RV4-r(7-methoxy-2-phenyl-6-vinylquinolin-4-yl ' )oxy1-l-((2 ⁇ -2- ⁇ r(pent-4-en- l-yloxy)carbonyllamino)non-8-enoyl)-L-prolinate
- Step 2 (4R)-4-r(7-Methoxy-2-phenyl-6-vinylquinolin-4-vnoxyl-l-((2S)-2-(r(pent-4-en-l- yloxy)carbonvnamino ⁇ non-8-enoylVL-proline
- Step 3 Pent-4-en-l-yl r ⁇ 5)-l-(((25,4RV2-(r((l/?,25 f )-l-(r(cvclopropylsulfonvnamino1- carbonvU-2-vinylcvclopropyl ' )amino]carbonyl
- Step 4 (3R,6S,9R ⁇ 15',12Za9S,26E)-N-(Cvclopropylsulfonvn-29-methoxy-7,2L37-trioxo-33- phenyl-2,22-dioxa-5,8,2032-tetraazahexacvclor26.6.2.13,6.15J9.09.11.03L351octatriaconta- 1(35), 12,26,28,30,3 L33,35-octaene-9-carboxamide
- Step 1 Methyl (4R)-l-r(25 f )-2-( ⁇ r(2,2-dimethylpent-4-en-l-vnoxylcarbonyl
- Step 2 (AK)-X - ⁇ (2S)-2-( ⁇ Ff 2.2-Dimethylpent-4-en-l -vDoxyi carbon yli amino)non-8-enoyll-4-r(7- methox ⁇ -2-phenyl-6-vinylquinolin-4-yl)oxy1-L-proline
- Step 3 Ethyl (lR2S)-UU4R)-U(2S)-2-(i ⁇ (22-dimethyhent-4-en-l- yl)oxy]carbonyl
- Step 4 Ethyl r3R.6 ⁇ 9R.11 ⁇ 12Z.195.26E)-29-methoxy-24.24-dimethyl-7.21.37-trioxo-33- phenyl-2,22-dioxa-5,8,20,32-tetraazahexacvclo[26.6.2.1 3 ' 6 .l 5 ' 19 .0 9 ' H .0 31 ' 35 1octatriaconta-
- Step 5 (3R6S.9R ⁇ 1 ⁇ 12Z.19S.26E)-29-Methoxy-24,24-dimethyl-7,21,37-trioxo-33-phenyl- 2,22-dioxa-5,8,20 ⁇ 32-tetraazahexacvclor26.6.2.1 3 ' 6 .l 5 ' 19 .0 9 ' n .0 31 ' 35 loctatriaconta- l(35U2,26,28,30,3U3,35-octaene-9-carboxylic acid
- Example 3 To a solution of Example 3 (250 mg, 0.133 mmol) in THF (5 mL) was added CDI (68.8 mg, 0.424 mmol). The reaction mixture was stirred at 40°C for 5 hours. Cyclopropanesulfonamide (61.7 mg, 0.51 mmol) and DBU (0.102 mL, 0.679 mmol) were added and the reaction mixture was stirred at 40°C for 18 hours. The solution was concentrated and purified on a reverse-phase HPLC, eluting with 5% to 95% CH 3 CN in (0.15 % TFA in water) to give Example 4 (195 mg).
- Example 5 was prepared from Example 4 according to the procedure described for Example 2.
- Step 1 Ethyl (4RV4-r(7-bromo-6-methoxyisoquinolin-l-yl ' )oxyl-l-((2S)-2-r( ' t- butoxycarbonyl)amino " lnon-8-enovU-L-prolinate
- Step 2 ( ' 4R)-4-r(7-Bromo-6-methoxyisoquinolin-l-yl)oxyl-l-((2.y)-2-r( ' tgrt- butoxycarbonyl)amino1non-8-enoyl ⁇ -L-proline
- Step 3 Ethyl (lie.Z ⁇ -l-rfr ⁇ -rrT-bromo- ⁇ -methoxyisoquinolin-l-vnoxyi-l-i ⁇ -rrt- butoxycarbonyl)amino]non-8-enovU-L-prolyl)amino]-2-vinylcvclopropanecarboxylate
- Step 4 Ethyl (2R.65'.12Z.13aS',14a/?J6aS)-2-r( ' 7-bromo-6-methoxyisoquinolin-l-vnoxyl-6-r(t- butoxycarbonvnamino1-5J6-dioxo-l,23.6J ⁇ 9n ⁇ i,13a,14.15.16.16a- tetradecahvdrocvcloproparelpyrrolo[ 1 ,2- ⁇ l [ 1 ⁇ Idiazacyclopentadecine- 14a(5H)-carboxylate
- Step 5 Ethyl (l ⁇ ⁇ ⁇ '.UZ.lSaS',14aR,16aS)-6-[(t-butoxycarbonvnaminol-2-[(6-methoxy-7- vinylisoquinolm-1-yl)oxyl-5,16-dioxo-l,2.3.6,7,8.9.10.11.13aJ4.15.16.16a- tetradecahydrocycloproparelpyrrolor 1 ,2- ⁇ l [ 1 ,4]diazacyclopentadecine- 14a(5H)-carboxylate
- Step 6 Ethyl (2R,65'.12Z.13aS.14aRJ6a5)-6-amino-2-r( ' 6-methoxy-7-vinylisoquinolin-l-yl ' )oxyl-
- Step 7 Ethyl r2R.6S.12Z.13aSa4aR.16a ⁇ )-6-( ⁇ r(2,2-dimethylpent-4-en-l- yl)oxy]carbonvU amino)-2-[(6-methoxy-7-vinylisoquinolin- l-vDoxyi-5, 16-dioxo- 1,2,3,6,7,8,9,10.1 L ⁇ a.H.lSJ ⁇ .l ⁇ a-tetradecahvdrocvcloproparelpyrrolon ⁇ - a] ⁇ 1 ,4] diazacyclopentadecine- 14a(5H)-carboxylate
- Step 8 Ethyl (3 ⁇ .6 ⁇ 9R,l lS,12Z,19S.26E)-29-methoxy-24.24-dimethyl-7,21.37-trioxo-2.22- dioxa-5,8,20,34-tetraazahexacvclor26.6.2.1 3 - 6 .l 5 '' 9 .0 9 '".0 3U35 loctatriaconta- l(35U2,26,28.30.31.33.35-octaene-9-carboxylate
- Step 9 (3R6SSR ⁇ lSa2Z.19S,26E)-29-methoxy-24,24-dimethyl-7.21.37-trioxo-2,22-dioxa-
- Step 10 (3R.6S3R ⁇ lS.12Z.19S.26E)-iV-(CvclopropylsulfonylV29-methoxy-24.24-dimethyl-
- Step 1 Ethyl (25 l ,65J2ZJ3aS'.14a/?,16a ⁇ -6-amino-2-(r(4-bromophenyl)sulfonylloxyl-5,16- dioxo-12 ⁇ 6J ⁇ 9J0J lJ3ai4J5J6J6a-tetradecahvdrocvclopropare1pyr ⁇ olo[l,2- ⁇ r 1 ⁇ ldiazacyclopentadecine- 14a(5H)-carboxylate hydrochloride
- Step 3 Ethyl (25',65'J2Z,13a 1 S',14aRa6ay)-2- ⁇ r(4-bromophenyl)sulfonvnoxyl-5.16-dioxo-6- [( ⁇ [(li ⁇ iO ⁇ -penM-en-l-ylcvclopentylloxylcarbonvDamino ' l- l ⁇ .S. ⁇ J. ⁇ .g.lO.l lJSa.HJSJ ⁇ J ⁇ a-tetradecahvdrocvcloproparelpyrrolo ⁇ - al r 1 ⁇ Idiazacyclopentadecine- 14a(5H)-carbox ⁇ late
- Step 5 Ethyl (2&6£12Z.13a£14a£.16a ⁇ -5,16-dioxo-6-r( ⁇ r ⁇ iURV2-pent-4-en-l- ylcvclopentylloxy ⁇ carbonyl)amino1-2-r(2-vinylquinolin-3-yl)oxyl- 1.2.3.6,7.8,9,10,1 USa.H.lS.l ⁇ J ⁇ a-tetradecahvdrocvcloproparglpyrrolo ⁇ - ⁇ ⁇ 1 ⁇ ldiazacyclopentadecine- 14a(5H)-carboxvlate
- Step 6 (3/?.15E.20R.24.R.285.34Z,36S,38R,41 ⁇ )-N-(Cvclopropylsulfonvn-26,40.42-trioxo-4,25- dioxa-lJ3.27.39-tetraazaheptacvclor26.13.1.1 3 ' 41 .Q 5 ' 14 .0 7 - 12 .0 20>24 .0 36 ' 38 1tritetraconta-
- Example 18 was prepared according to the procedure described for Example 17 using 3-vinylquinoxalin-2-ol in place of 2-vnylquinolin-3-ol in step 5.
- LCMS (M+H) + 777.2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07839741.1T ES2444575T3 (en) | 2006-10-27 | 2007-10-23 | HCV NS3 protease inhibitors |
US12/446,789 US8377874B2 (en) | 2006-10-27 | 2007-10-23 | HCV NS3 protease inhibitors |
AU2007318164A AU2007318164B2 (en) | 2006-10-27 | 2007-10-23 | HCV NS3 protease inhibitors |
CN200780048120.7A CN101568346B (en) | 2006-10-27 | 2007-10-23 | HCV NS3 protease inhibitor |
CA002667032A CA2667032A1 (en) | 2006-10-27 | 2007-10-23 | Hcv ns3 protease inhibitors |
EP07839741.1A EP2083844B1 (en) | 2006-10-27 | 2007-10-23 | Hcv ns3 protease inhibitors |
JP2009534617A JP5352464B2 (en) | 2006-10-27 | 2007-10-23 | HCV NS3 protease inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85479406P | 2006-10-27 | 2006-10-27 | |
US60/854,794 | 2006-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008057208A2 true WO2008057208A2 (en) | 2008-05-15 |
WO2008057208A3 WO2008057208A3 (en) | 2008-10-30 |
Family
ID=39364975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/022452 WO2008057208A2 (en) | 2006-10-27 | 2007-10-23 | Hcv ns3 protease inhibitors |
Country Status (8)
Country | Link |
---|---|
US (1) | US8377874B2 (en) |
EP (1) | EP2083844B1 (en) |
JP (1) | JP5352464B2 (en) |
CN (1) | CN101568346B (en) |
AU (1) | AU2007318164B2 (en) |
CA (1) | CA2667032A1 (en) |
ES (1) | ES2444575T3 (en) |
WO (1) | WO2008057208A2 (en) |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010036551A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2010065577A1 (en) * | 2008-12-04 | 2010-06-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
US7767660B2 (en) | 2006-12-20 | 2010-08-03 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7781422B2 (en) | 2006-12-20 | 2010-08-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
US20110123496A1 (en) * | 2009-10-19 | 2011-05-26 | Yonghua Gai | Bismacrocyclic compounds as hepatitis c virus inhibitors |
US7973040B2 (en) | 2008-07-22 | 2011-07-05 | Merck Sharp & Dohme Corp. | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
US7989438B2 (en) | 2007-07-17 | 2011-08-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Therapeutic compounds |
WO2011091757A1 (en) | 2010-01-27 | 2011-08-04 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as hcv inhibitors |
US8101595B2 (en) | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8178520B2 (en) | 2006-05-15 | 2012-05-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic compounds as antiviral agents |
US8216999B2 (en) | 2005-07-20 | 2012-07-10 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8314062B2 (en) | 2006-06-23 | 2012-11-20 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
EP2432318A4 (en) * | 2009-05-22 | 2012-11-21 | Sequoia Pharmaceuticals Inc | Bimacrocyclic hcv ns3 protease inhibitors |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2013028470A1 (en) | 2011-08-19 | 2013-02-28 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8648037B2 (en) | 2010-09-21 | 2014-02-11 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived HCV serine protease inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102317306B (en) * | 2008-12-15 | 2014-07-30 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US8877929B2 (en) | 2008-09-04 | 2014-11-04 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
US8889871B2 (en) | 2002-05-20 | 2014-11-18 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8962810B2 (en) | 2011-06-16 | 2015-02-24 | AB Pharma Ltd. | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US9120818B2 (en) | 2010-12-14 | 2015-09-01 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US9163061B2 (en) | 2007-12-21 | 2015-10-20 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US9296782B2 (en) | 2012-07-03 | 2016-03-29 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9499550B2 (en) | 2012-10-19 | 2016-11-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9676785B2 (en) | 2007-12-21 | 2017-06-13 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US9694086B2 (en) | 2007-12-21 | 2017-07-04 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US9738661B2 (en) | 2006-10-27 | 2017-08-22 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US9873707B2 (en) | 2013-10-18 | 2018-01-23 | Merck Sharp & Dohme Corp. | Methods and intermediates for preparing macrolactams |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6038179B2 (en) | 2012-01-11 | 2016-12-07 | アッヴィ・インコーポレイテッド | Method for producing HCV protease inhibitor |
BR112015007887A2 (en) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compounds useful for making hcv protease inhibitors |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
CA2294562C (en) | 1997-08-11 | 2005-07-26 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
IL134232A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
IT1299134B1 (en) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | PROCEDURE FOR THE PRODUCTION OF PEPTIDES WITH PROTEAS INHIBITING THE NS3 PROTEASIS OF THE HCV VIRUS, PEPTIDES SO OBTAINABLE AND PEPTIDES |
JP2002504558A (en) | 1998-02-25 | 2002-02-12 | エモリー ユニバーシテイ | 2'-fluoronucleoside |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
DK1066247T3 (en) | 1998-03-31 | 2007-04-02 | Vertex Pharma | Inhibitors of serine proteases, especially hepatitis C virus NS3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
EP1106626B1 (en) | 1998-08-10 | 2003-05-28 | Hokkaido Electric Power Company, Incorporated | Process for the preparation of regular glycopeptides |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
ATE248835T1 (en) | 1999-06-25 | 2003-09-15 | Vertex Pharma | PRODRUGS OF IMPDH-INHIBITING CARBAMATES |
IL145071A0 (en) | 1999-12-27 | 2002-06-30 | Japan Tobacco Inc | Fused ring compounds and pharmaceutical compositions containing the same |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
EA200200778A1 (en) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION |
AU2001253124A1 (en) * | 2000-04-05 | 2001-10-23 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
AU2001253206A1 (en) | 2000-04-05 | 2001-10-23 | Tularik, Inc. | Ns5b hcv polymerase inhibitors |
BR0110023A (en) | 2000-04-13 | 2003-12-30 | Pharmasset Ltd | Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
US6921735B2 (en) | 2000-08-10 | 2005-07-26 | The Trustees Of Boston College | Recyclable metathesis catalysts |
US6955174B2 (en) | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
US6809101B2 (en) | 2000-09-01 | 2004-10-26 | Shionogi & Co., Ltd. | Compounds having anti-hepatitis C virus effect |
DK1411954T3 (en) | 2000-10-18 | 2011-03-14 | Pharmasset Inc | Modified nucleosides to treat viral infections and abnormal cellular proliferation |
CA2430458A1 (en) | 2000-12-12 | 2002-06-20 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
AU2002232660A1 (en) | 2000-12-15 | 2002-06-24 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
EP1346724A4 (en) | 2000-12-26 | 2004-11-17 | Mitsubishi Pharma Corp | Remedies for hepatitis c |
SI1355916T1 (en) | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
JP4537057B2 (en) | 2001-08-14 | 2010-09-01 | テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and treatment |
AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
JP2005536440A (en) | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | Methods and compositions for the treatment of flaviviruses and pestiviruses using nucleosides modified at the 4 'position |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
EP1465862A1 (en) | 2002-01-17 | 2004-10-13 | SmithKline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
US7323453B2 (en) | 2002-02-13 | 2008-01-29 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
JP2005530759A (en) | 2002-05-06 | 2005-10-13 | ジェネラブズ テクノロジーズ インコーポレーティッド | Nucleoside derivatives for treating hepatitis C virus infection |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP1551421A2 (en) | 2002-06-21 | 2005-07-13 | Merck & Co. Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003269892A1 (en) | 2002-06-27 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
EP2799442A1 (en) | 2002-06-28 | 2014-11-05 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
EP1536804A4 (en) | 2002-06-28 | 2007-10-31 | Idenix Cayman Ltd | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2490200C (en) | 2002-06-28 | 2012-01-03 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
WO2004007512A2 (en) | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003254657A1 (en) | 2002-07-25 | 2004-02-16 | Micrologix Biotech Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
US8093380B2 (en) | 2002-08-01 | 2012-01-10 | Pharmasset, Inc. | Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections |
NZ538457A (en) | 2002-09-30 | 2008-04-30 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
HN2003000348A (en) | 2002-11-01 | 2008-10-14 | Viropharma Inc | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND VIRAL INFECTION OF HEPATITIS C AND ASSOCIATED ILLNESSES. |
US20040254159A1 (en) | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
MXPA05010338A (en) | 2003-04-02 | 2005-11-17 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis c viral protease inhibitors. |
GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
ES2386161T3 (en) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Process to separate a mixture of alkyl ester enantiomers using an enzyme |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
BRPI0410846B8 (en) | 2003-05-30 | 2021-05-25 | Gilead Pharmasset Llc | nucleoside and pharmaceutical composition comprising it |
GB0313250D0 (en) | 2003-06-09 | 2003-07-16 | Angeletti P Ist Richerche Bio | Therapeutic agents |
CA2528294A1 (en) | 2003-06-19 | 2005-01-06 | F. Hoffmann-La Roche Ag | Processes for preparing 4'-azido nucleoside derivatives |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
GB0321003D0 (en) | 2003-09-09 | 2003-10-08 | Angeletti P Ist Richerche Bio | Compounds, compositions and uses |
GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ATE495185T1 (en) | 2004-01-21 | 2011-01-15 | Boehringer Ingelheim Int | MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS |
ATE428714T1 (en) | 2004-02-24 | 2009-05-15 | Japan Tobacco Inc | CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITORS |
GB0413087D0 (en) | 2004-06-11 | 2004-07-14 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0416396D0 (en) | 2004-07-22 | 2004-08-25 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
WO2006021341A1 (en) | 2004-08-23 | 2006-03-02 | F. Hoffmann-La Roche Ag | Antiviral 4’-azido-nucleosides |
GB0419850D0 (en) | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
AU2005298412B2 (en) | 2004-10-26 | 2011-06-09 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
GB0509326D0 (en) | 2005-05-09 | 2005-06-15 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
WO2007016441A1 (en) * | 2005-08-01 | 2007-02-08 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
WO2007028789A1 (en) | 2005-09-07 | 2007-03-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Quinazoline derivatives as antiviral agents |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0519797D0 (en) | 2005-09-29 | 2005-11-09 | Istituto Di Ricerche D Biolog | Therapeutic agents |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
EP2029741A4 (en) | 2006-06-08 | 2011-03-16 | Merck Sharp & Dohme | A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences cloned from clinical samples |
US7953587B2 (en) * | 2006-06-15 | 2011-05-31 | Schlumberger Technology Corp | Method for designing and optimizing drilling and completion operations in hydrocarbon reservoirs |
GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CN101583372A (en) | 2006-10-24 | 2009-11-18 | 默克公司 | HCV NS3 protease inhibitors |
BRPI0718161A2 (en) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND. |
CN101568346B (en) | 2006-10-27 | 2015-11-25 | 默沙东公司 | HCV NS3 protease inhibitor |
CA2705449C (en) | 2006-11-09 | 2017-01-10 | Twinblade Technologies Holding Sweden Ab | Hub device |
US20100143886A1 (en) | 2007-03-09 | 2010-06-10 | Ludmerer Steven W | In vivo hcv resistance to anti-viral inhibitors |
NZ582090A (en) | 2007-06-29 | 2012-05-25 | Gilead Sciences Inc | Purine derivatives and their use as modulators of toll-like receptor 7 |
EP2178902B1 (en) | 2007-07-19 | 2012-11-28 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Macrocyclic compounds as antiviral agents |
CL2008003384A1 (en) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Macrocyclic quinoxaline derived compounds, serine protease inhibitors; pharmaceutical composition comprising them; and its use in the treatment of hepatitis c. |
MX2010005261A (en) | 2007-11-14 | 2010-10-15 | Enanta Pharm Inc | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors. |
-
2007
- 2007-10-23 CN CN200780048120.7A patent/CN101568346B/en not_active Expired - Fee Related
- 2007-10-23 CA CA002667032A patent/CA2667032A1/en not_active Abandoned
- 2007-10-23 ES ES07839741.1T patent/ES2444575T3/en active Active
- 2007-10-23 US US12/446,789 patent/US8377874B2/en active Active
- 2007-10-23 AU AU2007318164A patent/AU2007318164B2/en not_active Ceased
- 2007-10-23 WO PCT/US2007/022452 patent/WO2008057208A2/en active Application Filing
- 2007-10-23 JP JP2009534617A patent/JP5352464B2/en not_active Expired - Fee Related
- 2007-10-23 EP EP07839741.1A patent/EP2083844B1/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP2083844A4 * |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9636375B2 (en) | 2002-05-20 | 2017-05-02 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8889871B2 (en) | 2002-05-20 | 2014-11-18 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8216999B2 (en) | 2005-07-20 | 2012-07-10 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8178520B2 (en) | 2006-05-15 | 2012-05-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic compounds as antiviral agents |
US8314062B2 (en) | 2006-06-23 | 2012-11-20 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US9738661B2 (en) | 2006-10-27 | 2017-08-22 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8101595B2 (en) | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
US7781422B2 (en) | 2006-12-20 | 2010-08-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7767660B2 (en) | 2006-12-20 | 2010-08-03 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7989438B2 (en) | 2007-07-17 | 2011-08-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Therapeutic compounds |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
US9163061B2 (en) | 2007-12-21 | 2015-10-20 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US9676785B2 (en) | 2007-12-21 | 2017-06-13 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US9694086B2 (en) | 2007-12-21 | 2017-07-04 | Celgene Car Llc | HCV protease inhibitors and uses thereof |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8080654B2 (en) | 2008-07-22 | 2011-12-20 | Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
JP2011528713A (en) * | 2008-07-22 | 2011-11-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
US7973040B2 (en) | 2008-07-22 | 2011-07-05 | Merck Sharp & Dohme Corp. | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
US8877929B2 (en) | 2008-09-04 | 2014-11-04 | Bristol-Myers Squibb Company | Process for synthesizing substituted isoquinolines |
JP2013163680A (en) * | 2008-09-11 | 2013-08-22 | Abbott Lab | Macrocyclic hepatitis c serine protease inhibitor |
US9309279B2 (en) | 2008-09-11 | 2016-04-12 | Abbvie Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US8420596B2 (en) | 2008-09-11 | 2013-04-16 | Abbott Laboratories | Macrocyclic hepatitis C serine protease inhibitors |
US8642538B2 (en) | 2008-09-11 | 2014-02-04 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CN102227435A (en) * | 2008-09-29 | 2011-10-26 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
WO2010036551A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP2012511004A (en) * | 2008-12-04 | 2012-05-17 | ブリストル−マイヤーズ スクイブ カンパニー | Hepatitis C virus inhibitor |
CN102307890A (en) * | 2008-12-04 | 2012-01-04 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
CN102307890B (en) * | 2008-12-04 | 2014-03-05 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
WO2010065577A1 (en) * | 2008-12-04 | 2010-06-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN102317306B (en) * | 2008-12-15 | 2014-07-30 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
EP2432318A4 (en) * | 2009-05-22 | 2012-11-21 | Sequoia Pharmaceuticals Inc | Bimacrocyclic hcv ns3 protease inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
US20110123496A1 (en) * | 2009-10-19 | 2011-05-26 | Yonghua Gai | Bismacrocyclic compounds as hepatitis c virus inhibitors |
US9193740B2 (en) * | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
WO2011091757A1 (en) | 2010-01-27 | 2011-08-04 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as hcv inhibitors |
US8648037B2 (en) | 2010-09-21 | 2014-02-11 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived HCV serine protease inhibitors |
US9220748B2 (en) | 2010-09-21 | 2015-12-29 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived HCV serine protease inhibitors |
US9120818B2 (en) | 2010-12-14 | 2015-09-01 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9527885B2 (en) | 2011-05-05 | 2016-12-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US10201541B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8962810B2 (en) | 2011-06-16 | 2015-02-24 | AB Pharma Ltd. | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof |
US9238604B2 (en) | 2011-08-19 | 2016-01-19 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US9242917B2 (en) | 2011-08-19 | 2016-01-26 | Merck Sharp & Dohme Limited | Crystal forms of a HCV protease inhibitor |
WO2013028470A1 (en) | 2011-08-19 | 2013-02-28 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US9073825B2 (en) | 2011-08-19 | 2015-07-07 | Merck Sharp & Dohme Limited | Methods and intermediates for preparing macrolactams |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US10603318B2 (en) | 2012-07-03 | 2020-03-31 | Gilead Pharmasset Llc | Inhibitors of hepatitis C virus |
US10335409B2 (en) | 2012-07-03 | 2019-07-02 | Gilead Pharmasset Llc | Inhibitors of hepatitis C virus |
US9296782B2 (en) | 2012-07-03 | 2016-03-29 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
US9499550B2 (en) | 2012-10-19 | 2016-11-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
US9873707B2 (en) | 2013-10-18 | 2018-01-23 | Merck Sharp & Dohme Corp. | Methods and intermediates for preparing macrolactams |
US9333204B2 (en) | 2014-01-03 | 2016-05-10 | Abbvie Inc. | Solid antiviral dosage forms |
US9744170B2 (en) | 2014-01-03 | 2017-08-29 | Abbvie Inc. | Solid antiviral dosage forms |
US10105365B2 (en) | 2014-01-03 | 2018-10-23 | Abbvie Inc. | Solid antiviral dosage forms |
Also Published As
Publication number | Publication date |
---|---|
CN101568346B (en) | 2015-11-25 |
EP2083844B1 (en) | 2013-11-27 |
EP2083844A4 (en) | 2010-12-01 |
JP5352464B2 (en) | 2013-11-27 |
CA2667032A1 (en) | 2008-05-15 |
EP2083844A2 (en) | 2009-08-05 |
AU2007318164A1 (en) | 2008-05-15 |
JP2010507660A (en) | 2010-03-11 |
US8377874B2 (en) | 2013-02-19 |
ES2444575T3 (en) | 2014-02-25 |
AU2007318164B2 (en) | 2013-02-07 |
CN101568346A (en) | 2009-10-28 |
US20100286185A1 (en) | 2010-11-11 |
WO2008057208A3 (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007318164B2 (en) | HCV NS3 protease inhibitors | |
EP2086982B1 (en) | Hcv ns3 protease inhibitors | |
AU2007309488B2 (en) | HCV NS3 protease inhibitors | |
EP1913016B1 (en) | Macrocyclic peptides as hcv ns3 protease inhibitors | |
EP1910404B9 (en) | Hcv ns3 protease inhibitors | |
CA2720850A1 (en) | Hcv ns3 protease inhibitors | |
EP2618665A1 (en) | Hcv ns3 protease inhibitors | |
WO2006119061A2 (en) | Hcv ns3 protease inhibitors | |
EP2079479A2 (en) | Hcv ns3 protease inhibitors | |
WO2011014487A1 (en) | Hepatitis c virus ns3 protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780048120.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07839741 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2667032 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007318164 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12446789 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2009534617 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007839741 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007318164 Country of ref document: AU Date of ref document: 20071023 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3309/DELNP/2009 Country of ref document: IN |